Mirtazapine Sandoz 30 (Mirtazapine)

Mirtazapine works by blocking presynaptic α2‑adrenergic receptors, which increases norepinephrine release, and by antagonising serotonergic 5‑HT2 and 5‑HT3 receptors as well as H1 histamine receptors. This combined action enhances serotonergic and noradrenergic neurotransmission, contributing to its antidepressant effect.

The appropriate dose of Mirtazapine Sandoz 30 is determined by the prescribing clinician based on the individual patient's condition, response, and tolerability. Dosage adjustments are made according to clinical judgment and patient needs.

The safety of mirtazapine in pregnancy and lactation has not been definitively established. Healthcare providers should weigh potential benefits against possible risks and consider alternative treatments when appropriate.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mirtazapine belongs to the NaSSA class, differing from SSRIs and SNRIs by its combined noradrenergic and specific serotonergic activity and strong antihistamine effect. This profile often results in pronounced sedation and weight gain, which can be advantageous for patients with insomnia or appetite loss, but may be less suitable for those concerned about these side effects.

Store the tablets at ambient temperature, preferably below 25 °C. Keep them in the original blister pack or container, protect from moisture and direct light, and ensure they are out of reach of children.

Mirtazapine Sandoz 30 is taken orally, usually once daily in the evening with or without food, as directed by a healthcare professional. Swallow the tablet whole; do not crush or chew unless specifically instructed.

Serious risks include agranulocytosis or severe neutropenia, severe allergic reactions such as anaphylaxis, seizures, and the potential for emergence or worsening of suicidal thoughts, particularly during early treatment or dose changes.

Mirtazapine should be avoided in patients with known hypersensitivity to the drug, those currently taking monoamine oxidase inhibitors, or individuals with a history of severe hepatic impairment without appropriate medical supervision.